Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
Go back to Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia| (NASDAQ: NERV) | Delayed: 4.62 -0.15 (3.14%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.77 | 52 Week High | $15.84 | |||
| Open | $4.69 | 52 Week Low | $3.45 | |||
| Day High | $4.73 | P/E | N/A | |||
| Day Low | $4.56 | EPS | $0.00 | |||
| Volume | 166,227 | |||||
